title: A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats.
abstract: Curcumin is an inhibitor of p300 histone acetyltransferase activity, which is associated with the deterioration of heart failure. We reported that native curcumin, at a dosage of 50 mg/kg, prevented deterioration of the systolic function in rat models of heart failure. To achieve more efficient oral pharmacological therapy against heart failure by curcumin, we have developed a novel drug delivery system (DDS) which markedly increases plasma curcumin levels. At the dosage of 0.5 mg/kg, DDS curcumin but not native curcumin restored left ventricular fractional shortening in post-myocardial infarction rats. Thus, our DDS strategy will be applicable to the clinical setting in humans.
authors.affiliation: Human Health Sciences, Graduate School of Medicine, Kyoto University, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Sunagawa
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Wada
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sasaki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Imaizumi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fukuda
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Katanasaka
authors.forename: Akira
authors.initials: A
authors.lastname: Shimatsu
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kakeya
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Fujita
authors.forename: Koji
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Morimoto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003474:Curcumin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D006170:Gum Arabic / Q000008:administration & dosage; D006333:Heart Failure / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006439:Hemodynamics; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D053149:Plant Gums / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D050880:p300-CBP Transcription Factors / Q000037:antagonists & inhibitors; D000099224:p300-CBP-Associated Factor
chemical_list: D002316:Cardiotonic Agents; D003474:Curcumin; D006170:Gum Arabic; D053149:Plant Gums; D050880:p300-CBP Transcription Factors; D000099224:p300-CBP-Associated Factor; C015253:gum ghatti